Oncolytics Biotech ® Inc. today announced that Matt Coffey, PhD, President and Chief Executive Officer of Oncolytics will take a medical leave of absence, effective immediately. Wayne Pisano, Chair of Oncolytics’ Board of Directors, will serve as the interim CEO during Dr. Coffey’s absence.
ILiAD Biotechnologies, LLC today announced the selection of Emmes Group, a global contract research and technology organization, to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1. ILiAD and Emmes Group are currently working to finalize the definitive agreement.
Oncoinvent Receives FDA Fast Track Designation for Radspherin ® as Treatment for Peritoneal Carcinomatosis from Ovarian Cancer.
Sun Pharmaceutical Industries Limited today announced the successful completion of the merger of Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) with its subsidiary.
NeuroBo Pharmaceuticals, Inc. today announced that it has entered into definitive agreements for the issuance and sale in a private placement of 4,325,701 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $3.93 per share (or per pre-funded warrant in lieu thereof).
IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced clinical program updates for IDE397, a potential first-in-class Phase 2 MAT2A inhibitor targeting MTAP-deletion solid tumors.
HUTCHMED Limited announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024.
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 Read More »
HighField Biopharmaceuticals2 other diseases, said naturally occurred diabetic monkeys experienced weight loss and HbA1c level reduction during an assessment period of two months following a single injection with HFG1.
Airway Therapeutics, Inc. announced it received the Whitsett Award for highest scoring abstracts from the Neonatal and Developing Lung Executive Committee at the American Thoracic Society 2024 International Conference.
OSE Immunotherapeutics SA, announced that the Company has entered into a commercial and revenue sharing agreement with leading global cancer center.
